All In Biotech

Drug Trial Radar · NCT06842186

A Phase 1/2a Study of WVE-007 in Adults Living With Overweight or Obesity

A Phase 1/2a, Randomized, Double-blind, Placebo-controlled Study of Ascending Doses of WVE-007 to Evaluate Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics in Adults Living With Overweight or Obesity

Last checked: Nov 19, 2026Latest source record: Oct 26, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingRandomized with 400 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

400

Planned (sponsor's estimate)

Start

Jan 31, 2025

Primary completion

Dec 2027

Study completion Dec 2027

Sponsor

Lead sponsor
Wave Life Sciences USA, Inc.Industry
Sponsor type
Industry
First posted
Feb 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 1 / Phase 2
Allocation
Randomized
Model
Parallel
Masking
Triple (participant, care provider, investigator)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years, up to 75 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this study is to assess the safety, tolerability, pharmacokinetics and pharmacodynamics of ascending doses of WVE-007 when administered subcutaneously (SC) . Part A is a single ascending dose study in adults living with overweight and obesity. The Part B of the study is a repeat dose administration in adult with obesity, with or without Type 2 Diabetes (T2D and non-T2D, respectively). In addition, Part B includes two dose groups that will receive WVE-007 and tirzepatide in adults living with obesity and T2D.

Conditions

  • Overweight and Obesity

Interventions

  • WVE-007Drug

    Stereopure siRNA oligonucleotide

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. The proportion of participants with treatment emergent adverse eventsTime frame: Day 1 through end of study

Locations

7 sites in 4 countries. Site status is shown where the registry gives one.

  • Arensia Exploratory Medicine, Inc. USA

    Phoenix, Arizona · Active not recruiting

  • Parexel International-EPCU Baltimore

    Baltimore, Maryland · Recruiting

  • ARENSIA Research Clinic

    Chisinau, Moldova · Recruiting

  • Arensia Clinics S.R.L.

    Bucharest, Romania · Recruiting

  • Spitalul Clinic Judetean De Urgenta Cluj

    Cluj-Napoca, Romania · Recruiting

  • Parexel International Early Phase Clinical Unit

    Harrow, United Kingdom · Recruiting

  • Simbec-Orion Clinical Pharmacology

    Merthyr Tydfil, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.